This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Raxibacumab
Description: ABthrax is a human monoclonal antibody that blocks the binding to cell surfaces of Bacillus anthracis protective antigen, the key facilitator of anthrax toxicity. This prevents anthrax toxins from entering and killing the cells.
Deal Structure: In August 1999, HGS entered into an antibody license agreement with CAT for the development of fully human antibody therapeutics for up to three target human proteins. In February 2000, HGS entered into a broader agreement with CAT that provides it with the right to use CAT's technology to develop and sell an unlimited number of fully human antibodies for therapeutic and diagnostic purposes. Pursuant to this agreement, HGS has obtained an exclusive license with respect to ABthrax. Under the 2000 agreement, HGS has paid to CAT $4.5 million in milestone payments through the end of 2006.
In June 2006, CAT was acquired by AstraZeneca.
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.
Partners: AstraZeneca PLC
Additional information available to subscribers only: